BiotechTube

KUC-7483 + Placebo + Tolterodine

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Overactive Bladder

Conditions

Overactive Bladder

Trial Timeline

— → —

NCT ID
NCT01004315

About KUC-7483 + Placebo + Tolterodine

KUC-7483 + Placebo + Tolterodine is a phase 3 stage product being developed by Kissei Pharmaceutical for Overactive Bladder. The current trial status is completed. This product is registered under clinical trial identifier NCT01004315. Target conditions include Overactive Bladder.

What happened to similar drugs?

10 of 20 similar drugs in Overactive Bladder were approved

Approved (10) Terminated (1) Active (9)
✅mirabegron + solifenacinAstellas PharmaApproved
✅Mirabegron + PlaceboAstellas PharmaApproved
✅SolifenacinAstellas PharmaApproved
🔄Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
🔄solifenacin succinateAstellas PharmaPhase 3
✅SolifenacinAstellas PharmaApproved
✅Mirabegron + Tolterodine ERAstellas PharmaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01004315Phase 3Completed

Competing Products

20 competing products in Overactive Bladder

See all competitors
ProductCompanyStageHype Score
mirabegron + solifenacinAstellas PharmaApproved
43
Mirabegron + PlaceboAstellas PharmaApproved
43
SolifenacinAstellas PharmaApproved
43
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
40
solifenacin succinateAstellas PharmaPhase 3
40
SolifenacinAstellas PharmaPre-clinical
26
BetanisAstellas PharmaPre-clinical
26
SolifenacinAstellas PharmaApproved
43
SolifenacinAstellas PharmaPhase 2
35
Mirabegron + Tolterodine ERAstellas PharmaApproved
43
mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverineAstellas PharmaPre-clinical
26
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
43
warfarin + YM178Astellas PharmaPhase 1
29
Solifenacin succinateAstellas PharmaPhase 3
40
solifenacin succinate + tolterodineAstellas PharmaPhase 3
40
Mirabegron tablet + Solifenacin tablet + Propiverine tablet + Imidafenacin tablet + Tolterodine capsuleAstellas PharmaApproved
43
Solifenacin succinateAstellas PharmaApproved
43
Mirabegron + PlaceboAstellas PharmaPhase 3
32
SolifenacinAstellas PharmaPre-clinical
26
Solifenacin succinate + TolterodineAstellas PharmaPhase 3
40